The MTA at 8.
Central Institute of Mental Health, Mannheim, Germany.
Tobias
T
Banaschewski
University Medical Center St. Radboud Nijmegen, The Netherlands.
Jan
J
Buitelaar
University of Dundee Dundee, United Kingdom.
David R
DR
Coghill
Faculty of Psychology and Education Vrije Universitat Amsterdam.
Joseph A
JA
Sergeant
University of Southampton Southampton, United Kingdom University of Ghent Ghent, Belgium.
Edmund
E
Sonuga-Barke
University of Cagliari Cagliari, Italy.
Alessandro
A
Zuddas
Kings College London, London.
Eric
E
Taylor
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use*; D000069445:Atomoxetine Hydrochloride; D001289:Attention Deficit Disorder with Hyperactivity / Q000628:therapy*; D001521:Behavior Therapy; D000697:Central Nervous System Stimulants / Q000627:therapeutic use*; D002648:Child; D003131:Combined Modality Therapy; D005500:Follow-Up Studies; D006801:Humans; D008134:Long-Term Care; D015337:Multicenter Studies as Topic; D011437:Propylamines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D012931:Social Environment; D016896:Treatment Outcome
D018759:Adrenergic Uptake Inhibitors; D000697:Central Nervous System Stimulants; D011437:Propylamines; D000069445:Atomoxetine Hydrochloride